Onco Actu du 10 mars 2016

	3.1 Tabac
No Smoking Day: why tobacco (still) isn’t a ‘done deal’ [Cancer Research UK] We’ve taken data about the UK population and the nation’s smoking rates, projecting them forward to understand what the impact of smoking would be if current trends continue. And it makes for worrying reading.
	3.3 Prévention - Vaccins
Early HPV vaccination provides the best protection [Karolinska Institutet] “Our conclusion is that the vaccine protects against serious prodromes of cervical cancer, with the greatest effect being when it’s given before the age of 16.”
	4.9 Dép., diag. & prono. - Sein
Mammograms may be missing some breast cancers, study shows [The Guardian] “That said, there are significant risks involved with tomosynthesis and ultrasound techniques that must be considered, particularly around false positives, as well as the cost, resource and training that would be required."
NHS breast cancer tests miss 3,500 tumours a year [The Telegraph] Samia al Qadhi, chief executive of Breast Cancer Care, said: “These exciting findings confirm that 3D mammography has the potential to change the future of breast screening."
	5. Traitements
Gene may worsen cancer outcome by speeding metabolism of drugs [The Institute of Cancer Research] The gene, called CYP3A7, is normally active only in infancy, but in some people it continues to be switched on into adulthood and over-activates their metabolism.
Partial breast radiotherapy cuts breast cancer side effects [Cancer Research UK] The researchers hope the trial results will contribute to changes in clinical practice worldwide. They also expect side effects to continue to be lower for women in the partial breast radiotherapy group after ten years, compared with those given the full dose of radiotherapy to the whole breast.
​Specific Form of CYP3A7 Gene Associated With Poor Outcomes for Patients With Several Cancer Types [AACR] “One possibility is that these patients break down the drugs that they are given to treat their cancer too fast. However, further independent studies that replicate our findings in larger numbers of patients and rule out biases are needed before we could recommend any changes to the treatment that cancer patients with the CYP3A7*1C allele receive.”
	5.10 Traitements - Essais
Atezolizumab in Patients With Locally Advanced and Metastatic Urothelial Carcinoma [ESMO] In this study patients aged ≥18 years with inoperable locally advanced or metastatic urothelial carcinoma whose disease had progressed after previous platinum-based chemotherapy were enrolled from 70 major academic medical centres and community oncology practices in Europe and North America.
	5.2 Pharma
Medivation's mystery cancer drug gets out from an FDA hold [FierceBiotech] The treatment, pidilizumab, was on the verge of a Phase II trial in patients with diffuse large B-cell lymphoma when the FDA placed a partial clinical hold on development last month. Medivation said it has since revised all study protocols to note that pidilizumab is not a PD-1 blocker, updating consent documents to ensure patients know what they're getting.
Aprea starts recruiting a U.S. team as it preps for PhII on p53 'Holy Grail' cancer drug [FierceBiotech] Stockholm-based Aprea AB is looking to add staffers on the East Coast in the U.S. after gaining an extra $51 million to spend as it ramps up mid-stage development work on its p53 drug APR-246 in ovarian cancer.
	5.2.3 Pharma - économie
Under siege, drug makers double down on advertising [STAT] The US and New Zealand are the only countries where drug makers are allowed to market prescription drugs directly to consumers. Increasingly, critics are expressing concern that expenditures on advertising drive up the price of drugs.
	6. Lutte contre les cancers
Can MedNexus, A Tech Startup, Help Patients Find Online Medical Information? [Forbes] MedNexus differs from other health-oriented websites by the way it offers, rather than provides, information. Essentially, it’s a unique search engine that ranks lay and professional medical resources based on reliability and clinical relevance.
	6.1 Observation
Annual Report to the Nation, 1975-2012 [National Cancer Institute] In contrast to the trends for most other cancers among both men and women, death rates due to liver cancer have increased the most compared with all cancer sites, and liver cancer incidence rates have also increased sharply.
Cancer Rates Spiked After Fukushima. But Don’t Blame Radiation [WIRED] So, will the kids who lived near the Fukishima plant suffer more thyroid cancer than their peers elsewhere? Well, yes. Probably. They are going to be screened more than most other kids, after all, and those screenings will turn up more thyroid cancer, just by virtue of the fact that people are looking for it.
	6.10 Politiques
Senate medical cures bills threatened by fight over NIH funding [STAT] A Senate package of biomedical innovation bills got bogged down in a partisan fight Wednesday over funding for the National Institutes of Health, foreshadowing more trouble ahead that could threaten the effort to accelerate the search for medical cures.